Nasdaq and S&P Hold Weekly Gains as Small Caps and Dow Slip Midweek CNW Group Wed, October 7, 2026 at 2:14 PM EDT 8 min read ^IXIC -0.30% ^RUT -1.18% CNI -1.76% ^GSPC -0.21% ^DJI -0.59% Trade CNI on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
PITTSBURGH, Oct. 7, 2026 /PRNewswire/ -- Stock Preachers Market Commentary - Major averages split this week as the Nasdaq Composite and S&P 500 held onto gains while the Dow Jones Industrial Average and Russell 2000 turned lower. The Nasdaq rose 1.05% for the week to 27,475.93, and the S&P 500 added 0.92% to 7,793.85, even as both indices fell on the latest session. The Dow slipped 0.06% for the week to 51,145.98, and the Russell 2000 dropped 1.42% to 2,792.80, underscoring a market where large-cap tech and biotech names are carrying the tape while smaller companies lag. Active Companies from around the markets with current developments this week include: RTX (NYSE: RTX), Eli Lilly and Company (NYSE: LLY), SAP SE (NYSE: SAP), International Business Machines Corporation (NYSE: IBM), and Canadian National Railway Company (TSX: CNR) (NYSE: CNI).
The Nasdaq Composite closed at 27,475.93, down 0.45% on the day but still up 1.05% for the week, with an RSI14 of 64.5 signaling a market near overbought territory. The index traded as high as 27,722.75 this week, matching its 52-week high, while support sits at 27,288.79 and 27,167.06. The S&P 500 closed at 7,793.85, down 0.32% on the day, with RSI14 at 59.4 and resistance at its 52-week high of 7,844.52.
The Dow Jones Industrial Average fell 0.73% on the day to 51,145.98, pushing its weekly change to negative 0.06%, with an RSI14 of 40.4 reflecting the index's relative weakness. The Russell 2000 posted the week's sharpest decline, down 1.32% on the day and 1.42% for the week to 2,792.80, with an RSI14 of 34.5 as small caps underperform large caps.
Volatility ticked higher with the VIX at 15.33, up 0.32 on the day though down 0.19 for the week, while the Nasdaq-100 volatility gauge (VXN) rose to 21.45. In commodities, gold fell 1.25% on the day to $4,134.90 per ounce and silver dropped 1.51% to $60.24, while WTI crude slipped to $88.89 a barrel. Natural gas jumped 3.82% on the day, and the 10-year Treasury yield rose to 5.32%.
The full report includes a detailed levels ladder for each index, a broader look at sector sentiment, and a preview of what to watch in the week ahead.
CONTINUED... Read this and more news from around this sector and may more at: Stock Preachers Market Commentary
In other industry developments and happenings in the market this week include:
RTX (NYSE: RTX) Raytheon, an RTX business, has secured a five-year contract with two additional option years, valued up to $24.4 billion, for Standard Missile-6 (SM-6) interceptors, boosting availability of the munition for offensive strikes and missile defense missions for the U.S. Navy.
"SM-6's multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand," said Phil Jasper, Raytheon President. "By continuously investing in our operations and facilities, we are removing constraints and boosting capacity to ensure we deliver this critical capability our sailors depend on."
SM-6 is described as the only combat-proven weapon able to perform anti-air warfare, anti-surface warfare and ballistic missile defense, and has been fired from various U.S. Navy ship-based platforms and land-based launchers.
Eli Lilly and Company (NYSE: LLY) The U.S. FDA has approved an additional indication for Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion, allowing its use as a first-line treatment for appropriate patients.
The approval is based on the BRUIN CLL-313 trial, where at a median follow-up of 28 months, progression-free survival was significantly improved with pirtobrutinib compared to bendamustine plus rituximab (HR=0.20; p
